Grifols (GRFS) Other Non-Current Liabilities (2010 - 2025)

Grifols (GRFS) reported Other Non-Current Liabilities of $138.5 million for Q4 2025, up 12862.92% on a YoY basis from N/an in Q4 2024, and up 12862.92% quarter-over-quarter from $1.1 million in Q4 2024.

Grifols (GRFS) Other Non-Current Liabilities (2010 - 2025) Analysis & Trends

Grifols has reported Other Non-Current Liabilities for 16 years, with the latest figure at $138.5 million in Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 12862.92% year-over-year to $138.5 million; the trailing twelve-month figure through Dec 2025 stood at $138.5 million (up 12862.92% YoY), and the FY2025 full-year result was $138.5 million, up 12862.92% from the prior year.
  • Other Non-Current Liabilities for Q4 2025 stood at $138.5 million, up from $1.1 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $138.5 million in Q4 2025, with the low at $1.1 million in Q4 2024.
  • Historically, Other Non-Current Liabilities has averaged $81.1 million across 5 years, with a median of $112.3 million in 2022.
  • Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 99.15% — and 2025, when it jumped 12862.92%.
  • Grifols' Other Non-Current Liabilities stood at $27.6 million in 2021, then surged by 306.93% to $112.3 million in 2022, then advanced by 12.03% to $125.8 million in 2023, then tumbled by 99.15% to $1.1 million in 2024, then jumped by 12862.92% to $138.5 million in 2025.
  • The last three Other Non-Current Liabilities figures came in at $138.5 million (Q4 2025), $1.1 million (Q4 2024), and $125.8 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Grifols 6.05 Bn 5.09 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 138.52 Mn
Dec 31, 2024 1.07 Mn
Dec 31, 2023 125.80 Mn
Dec 31, 2022 112.29 Mn
Dec 31, 2021 27.59 Mn
Dec 31, 2020 32.51 Mn
Sep 30, 2020 661.48 Mn
Mar 31, 2020 -2.10 Mn
Dec 31, 2019 8.89 Mn
Sep 30, 2019 497.08 Mn
Mar 31, 2019 -550,128.37
Dec 31, 2018 6.98 Mn
Sep 30, 2018 500.18 Mn
Jun 30, 2018 96.90 Mn
Mar 31, 2018 13.16 Mn
Dec 31, 2017 6.79 Mn
Jun 30, 2017 85.29 Mn
Mar 31, 2017 289,790.68
Dec 31, 2016 5.53 Mn
Sep 30, 2016 97.13 Mn